MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own3.01% Shs Outstand49.25M Perf Week0.00%
Market Cap118.20M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float47.57M Perf Month-18.09%
Income-10.10M PEG- EPS next Q-0.09 Inst Own14.60% Short Float2.81% Perf Quarter3.00%
Sales4.00M P/S29.55 EPS this Y33.10% Inst Trans-6.43% Short Ratio28.10 Perf Half Y-25.23%
Book/sh1.76 P/B1.36 EPS next Y-5.10% ROA- Target Price14.25 Perf Year-40.74%
Cash/sh1.37 P/C1.75 EPS next 5Y- ROE- 52W Range2.09 - 5.09 Perf YTD-10.45%
Dividend- P/FCF- EPS past 5Y8.70% ROI-12.20% 52W High-52.85% Beta1.17
Dividend %- Quick Ratio23.10 Sales past 5Y- Gross Margin- 52W Low14.83% ATR0.13
Employees11 Current Ratio23.10 Sales Q/Q- Oper. Margin- RSI (14)39.28 Volatility4.35% 5.04%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.32 Prev Close2.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume47.65K Price2.40
Recom- SMA20-5.29% SMA50-9.41% SMA200-21.22% Volume15,729 Change0.42%
Mar-10-21Initiated Maxim Group Buy $15
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
May-06-22 09:48AM  
Apr-21-22 07:00PM  
Apr-20-22 07:00PM  
Apr-12-22 11:00PM  
Apr-11-22 06:30AM  
Apr-08-22 09:38AM  
Apr-07-22 07:00PM  
Apr-06-22 11:15AM  
Mar-17-22 06:30AM  
Mar-15-22 06:30AM  
Mar-01-22 05:20AM  
Feb-28-22 06:30AM  
Feb-22-22 06:30AM  
Feb-14-22 01:12PM  
Feb-01-22 06:30AM  
Jan-31-22 06:30AM  
Jan-27-22 06:30AM  
Jan-26-22 06:30AM  
Dec-13-21 06:30AM  
Dec-10-21 06:30AM  
Nov-23-21 05:04AM  
Nov-22-21 06:30AM  
Nov-15-21 12:40PM  
Nov-11-21 06:00PM  
Nov-10-21 06:00PM  
Nov-03-21 07:30PM  
Oct-21-21 06:30AM  
Sep-02-21 11:00PM  
Sep-01-21 06:30AM  
Aug-30-21 06:30AM  
Aug-16-21 11:23AM  
11:03AM  
Aug-12-21 07:00PM  
Jul-06-21 06:30AM  
Jun-29-21 06:30AM  
Jun-28-21 08:37AM  
06:30AM  
Jun-26-21 07:34AM  
Jun-22-21 06:07AM  
Jun-21-21 06:30AM  
04:52AM  
Jun-18-21 03:23PM  
Jun-14-21 06:30AM  
Jun-07-21 06:30AM  
May-28-21 06:25AM  
May-17-21 09:04AM  
May-13-21 04:30PM  
May-05-21 08:00PM  
Apr-26-21 05:45AM  
Apr-22-21 06:30AM  
Apr-20-21 10:51AM  
Apr-19-21 06:30AM  
Apr-15-21 06:30AM  
Mar-15-21 05:35AM  
Mar-10-21 05:25PM  
10:03AM  
07:25AM  
Mar-09-21 04:00PM  
Mar-08-21 06:30AM  
Mar-03-21 07:46AM  
06:30AM  
Jan-31-21 06:00PM  
Jan-25-21 05:45AM  
04:32AM  
Jan-18-21 06:00PM  
Jan-11-21 09:30PM  
Dec-29-20 06:30AM  
Dec-15-20 06:30AM  
Nov-30-20 05:38PM  
Nov-25-20 06:30AM  
Nov-24-20 06:30AM  
Nov-12-20 10:00PM  
Oct-30-20 06:05AM  
Oct-26-20 11:47AM  
Oct-22-20 06:30AM  
Oct-21-20 06:30AM  
Oct-13-20 06:30AM  
Sep-24-20 09:24AM  
06:30AM  
Sep-23-20 10:37AM  
08:05AM  
06:30AM  
Sep-11-20 06:30AM  
Sep-02-20 11:23AM  
Sep-01-20 08:32AM  
06:30AM  
Aug-06-20 06:30AM  
Aug-04-20 07:40AM  
06:30AM  
Jul-28-20 08:13AM  
Jul-27-20 01:09PM  
06:30AM  
Jul-20-20 06:30AM  
Jul-02-20 05:47AM  
Jul-01-20 06:30AM  
Jun-26-20 08:28AM  
Jun-25-20 07:00PM  
Jun-24-20 08:07AM  
Jun-23-20 07:00PM  
Jun-12-20 12:31PM  
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matsuda KazukoChief Medical OfficerAug 23Option Exercise2.3060,000138,000322,996Aug 25 07:52 AM
IWAKI YUICHIPresident and CEOJul 09Option Exercise2.5439,583100,541966,933Jul 23 04:27 PM
Matsuda KazukoChief Medical OfficerJun 24Option Exercise2.50102,804256,622262,996Jun 28 04:50 PM